



DEPARTMENT OF DEFENSE

Office of the Secretary

Uniform Formulary Beneficiary Advisory Panel; Notice of Federal Advisory Committee Meeting

AGENCY: Under Secretary of Defense for Personnel and Readiness, Department of Defense (DoD).

ACTION: Notice of Federal Advisory Committee meeting.

SUMMARY: The DoD is publishing this notice to announce that the following Federal Advisory Committee meeting of the Uniform Formulary Beneficiary Advisory Panel (UFBAP) will take place.

DATES: Open to the public Wednesday, January 3, 2024, 10:00 a.m. to 1:00 p.m. (Eastern Standard Time).

ADDRESSES: The meeting will be held telephonically or via conference call. The phone number for the remote access on January 3, 2024, is: CONUS: 1-800-369-2046; OCONUS: 1-203-827-7030; PARTICIPANT CODE: 8546285.

These numbers and the dial-in instructions will also be posted on the UFBAP Website at:

<https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP>.

FOR FURTHER INFORMATION CONTACT: Designated Federal Official (DFO) Colonel Paul B. Carby, USA, 703-681-2890 (voice), dha.ncr.j-6.mbx.baprequests@health.mil (email). Mailing address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 22042-5101.

Website: <https://www.health.mil/Military-Health-Topics/Access-Cost-Quality-and-Safety/Pharmacy-Operations/BAP>. The most up-to-date changes to the meeting agenda can be found on the website.

SUPPLEMENTARY INFORMATION: Due to circumstances beyond the control of the

Designated Federal Officer, the Uniform Formulary Beneficiary Advisory Panel was unable to provide public notification required by 41 CFR 102-3.150(a) concerning its January 3, 2024 meeting. Accordingly, the Advisory Committee Management Officer for the Department of Defense, pursuant to 41 CFR 102-3.150(b), waives the 15-calendar day notification requirement. This meeting is being held under the provisions of 5 United States Code (U.S.C.) chapter 10 (commonly known as the Federal Advisory Committee Act or FACA), the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.140 and 102-3.150.

Purpose of the Meeting: The UFBAP will review and comment on recommendations made by the Pharmacy and Therapeutics Committee to the Director, Defense Health Agency regarding the Uniform Formulary.

Agenda:

1. 10:00 a.m. Sign In for UFBAP members
2. 10:10 a.m.-10:40 a.m. Welcome and Opening Remarks
 - a. Welcome, Opening Remarks, and Introduction of UFBAP Members by COL Paul B. Carby, DFO, UFBAP
 - b. Public Written Comments by COL Paul B. Carby, DFO, UFBAP
 - c. Opening Remarks by Mr. Jon Ostrowski, UFBAP Chair
 - d. Introductory Remarks by Dr. Edward Vonberg, Chief, Formulary Management Branch
3. 10:40 a.m.-11:45 a.m. Scheduled Therapeutic Class Reviews
4. 11:45 a.m.-12:30 p.m. Newly Approved Drugs Review
5. 12:30 p.m.-12:45 p.m. Pertinent Utilization Management Issues
6. 12:45 p.m.-1:00 p.m. Closing remarks
 - a. Closing Remarks by UFBAP Co-Chair
 - b. Closing Remarks by DFO, UFBAP

Meeting Accessibility: Pursuant to section 1009(a)(1) of the FACA and 41 CFR 102-3.140 through 102-3.165, and subject to the availability of phone lines, this meeting is open to the

public. Telephone lines are limited and available to the first 220 people dialing in. There will be 220 lines total: 200 domestic and 20 international, including leader lines.

Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102-3.140(c), and section 1009(a)(3) of title 5, U.S.C., interested persons or organizations may submit written statements to the UFBAP about its mission and/or the agenda to be addressed in this public meeting.

Written statements should be submitted to the UFBAP's DFO. The DFO's contact information can be found in the **FOR FURTHER INFORMATION CONTACT** section of this notice.

Written comments or statements must be received by the UFBAP's DFO no later than 8:00 a.m. EST, Wednesday, January 3, 2024, so they may be made available to the UFBAP for its consideration prior to the meeting. Written comments received are releasable to the public. The DFO will review all submitted written statements and provide copies to UFBAP.

Dated: January 2, 2024.

Natalie M. Ragland,

Alternate OSD Federal Register Liaison Officer,

Department of Defense.

[FR Doc. 2024-00050 Filed: 1/2/2024 4:15 pm; Publication Date: 1/5/2024]